MDLN Medline Inc.
Debt Financing ·
Medline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets.
We have not published a story on Medline yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $28.43 billion | $25.51 billion |
| Research and development | $80.0 million | $67.0 million |
| Net income (loss) | $1.16 billion | |
| Cash from operations | $1.74 billion | $1.77 billion |
| Cash and equivalents | $1.94 billion | $199.0 million |
| Short-term investments | $0 |
Medline Inc. trades under the ticker MDLN on NASDAQ.
Medline Inc. is listed on NASDAQ.
Our directory records Medline Inc. under United States.
aibio.space lists Medline Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$28.43 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Medline Inc. reported net income of $1.16 billion for the fiscal year ended Dec 31, 2025, and generated $1.74 billion of cash from operations, per its annual report to the SEC.
$80.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$2.68 billion in cash and short-term investments at Jun 27, 2026, per its 10-Q.
Our latest story on Medline, dated May 28, 2026: "Medline sells $1,250.0 million and $750.0 million in senior secured notes". Medline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets. Source.
Our latest debt story, dated May 28, 2026: "Medline sells $1,250.0 million and $750.0 million in senior secured notes". Medline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets. Source.
Press Follow on this page to add Medline to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Medline so far, in Debt Financing.
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio